Inactivation of Ebola virus and Middle East respiratory syndrome coronavirus in platelet concentrates and plasma by ultraviolet C light and methylene blue plus visible light, respectively (2018)

Peer-Reviewed Study · Eickmann M, Gravemann U, Handke W, et al. · May 6, 2018

Eickmann M et al., 2018-05-06: Plasma-spiking study showing the Theraflex MB-Plasma system reduces Ebola virus infectivity by at least 4.6 log to undetectable levels. In-vitro blood-product work; the same paper assigns Ebola in platelets to UVC, not MB.

MB/light decreased EBOV (≥4.6 log) and MERS-CoV (≥3.3 log) titers in plasma to nondetectable levels. Both THERAFLEX UV-Platelets (UVC) and THERAFLEX MB-Plasma (MB/light) effectively reduce EBOV and MERS-CoV infectivity in platelets and plasma, respectively.

Eickmann M et al., 2018-05-06: Plasma-spiking study showing the Theraflex MB-Plasma system reduces Ebola virus infectivity by at least 4.6 log to undetectable levels. In-vitro blood-product work; the same paper assigns Ebola in platelets to UVC, not MB. Study type: in vitro plasma and platelet spiking with cell-culture-derived Ebola and MERS-CoV. N/A. Country: Germany (Philipps University Marburg, with DRK Springe). MB plus visible light, Theraflex MB-Plasma; light doses varied; MB concentration not in abstract. Funding: grants from Forschungsgemeinschaft der DRK-Blutspendedienste and MacoPharma. Conflicts: two authors are MacoPharma employees; others received project grants from MacoPharma. Comparator: UVC system and untreated controls. Also filed as MTR-026 (claims C10, C3). Study type: lab.